[New trends in the treatment of moderate arterial hypertension].
Tomov
I
I
D000316:Adrenergic alpha-Agonists / Q000009:adverse effects / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002216:Captopril / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000517:prevention & control; D004232:Diuretics / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007008:Hypokalemia / Q000139:chemically induced; D008297:Male; D008722:Methods; D008875:Middle Aged; D012110:Reserpine / Q000627:therapeutic use; D012306:Risk
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D004232:Diuretics; D004656:Enalapril; D012110:Reserpine; D002216:Captopril
Novi nasoki za lechenie na lekostepennata arterialna khipertoniia.